McEwan P - Search Results

1

Development Of A Model To Predict Disease Progression In Autosomal Dominant Polycystic Kidney Disease (ADPKD).

McEwan P, Bennett Wilton H, Robinson P, Hadimeri H, Ong A, Ørskov B, Peces R, Sandford R, Scolari F, Walz G, Woon C, O'Reilly K. McEwan P, et al. Value Health. 2014 Nov;17(7):A564. doi: 10.1016/j.jval.2014.08.1870. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201867 Free article. No abstract available.

2

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.

McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, Cabrera MV, Walz G, O'Reilly K, Robinson P. McEwan P, et al. BMC Nephrol. 2018 Feb 13;19(1):37. doi: 10.1186/s12882-017-0804-2. BMC Nephrol. 2018. PMID: 29439650 Free PMC article. Clinical Trial.

3

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.

Bennett H, McEwan P, Hamilton K, O'Reilly K. Bennett H, et al. Among authors: mcewan p. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5. BMC Nephrol. 2019. PMID: 31014270 Free PMC article. Clinical Trial.

4

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.

Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Morgan CL, et al. Among authors: mcewan p. Thromb Res. 2009 May;124(1):37-41. doi: 10.1016/j.thromres.2008.09.016. Epub 2008 Dec 4. Thromb Res. 2009. PMID: 19062079

5

Review of utility values for economic modeling in type 2 diabetes.

Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Beaudet A, et al. Among authors: mcewan p. Value Health. 2014 Jun;17(4):462-70. doi: 10.1016/j.jval.2014.03.003. Epub 2014 May 17. Value Health. 2014. PMID: 24969008 Free article. Review.

6

Validation of the IMS CORE Diabetes Model.

McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. McEwan P, et al. Value Health. 2014 Sep;17(6):714-24. doi: 10.1016/j.jval.2014.07.007. Value Health. 2014. PMID: 25236995 Free article.

7

Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.

McEwan P, Bennett H, Ward T, Bergenheim K. McEwan P, et al. Pharmacoeconomics. 2015 Feb;33(2):149-61. doi: 10.1007/s40273-014-0225-z. Pharmacoeconomics. 2015. PMID: 25344660

8

Assessing the Relationship between Improved Life Expectancy Due to Better Cardiovascular Risk Factor Management and the Likelihood of Microvascular Complications in Type 2 Diabetes Mellitus.

McEwan P, Grant D, Foos V. McEwan P, et al. Value Health. 2014 Nov;17(7):A333. doi: 10.1016/j.jval.2014.08.633. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200583 Free article. No abstract available.

9

The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes - An Analysis From The Swedish Health Care Perspective.

Gordon J, McEwan P, Sabale U, Kartman B. Gordon J, et al. Among authors: mcewan p. Value Health. 2014 Nov;17(7):A344. doi: 10.1016/j.jval.2014.08.693. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200645 Free article. No abstract available.

10

Factors Associated With Weight Gain and Hypoglycaemia and The Impact Upon Hospitalisation in Type 2 Diabetes Patients Managed With Metformin Plus Sulphonylurea.

McEwan P, Gordon J, Evans M, Puelles J. McEwan P, et al. Value Health. 2014 Nov;17(7):A360. doi: 10.1016/j.jval.2014.08.783. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200733 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters